Table 3

Mixed-effects Cox regression model for SARS-CoV-2 infection*†

VariableHR95% CIP value
Age (per year)0.99(0.99 to 1.00)0.003
Race
 White(ref)
 Black1.48(1.21 to 1.82)<0.001
 Hispanic1.28(0.90 to 1.83)0.17
 Other1.56(1.11 to 2.19)0.01
Diabetes mellitus1.43(1.19 to 1.71)<0.001
Peripheral vascular disease1.73(1.28 to 2.35)<0.001
Obesity1.29(1.04 to 1.59)0.02
Corticosteroid use1.60(1.23 to 2.09)0.001
IBD Med category
 Mesalazine(ref)
 Thiopurine1.03(0.76 to 1.41)0.83
 Anti-TNF1.14(0.89 to 1.46)0.29
 Anti-TNF+tiopurine1.25(0.86 to 1.81)0.24
 Anti-TNF+MTX0.93(0.49 to 1.77)0.83
 Vedolizumab1.70(1.16 to 2.48)0.006
 No IBD Meds1.02(0.84 to 1.24)0.86
  • *US geographical region is treated as a random effect.

  • †The following variables were not retained in final multivariable models on the basis of p>0.05 or non-minimisation of Bayesian information criterion in associated models: sex, IBD diagnosis, hypertension, heart failure, arrhythmia, chronic obstructive pulmonary disease, renal failure.

  • IBD, inflammatory bowel disease; MTX, methotrexate; TNF, tumour necrosis factor.